Business Context and Reporting Period
Company: Akari Therapeutics Plc (Nasdaq: AKTX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Akari is an oncology company developing next-generation antibody-drug conjugates (ADCs) utilizing novel payloads. Following the November 2024 merger with Peak Bio, Inc., the company has pivoted its strategy to focus substantially on its ADC platform (lead candidate AKTX-101) and has suspended internal development of its legacy programs (nomacopan, PAS-nomacopan, and PHP-303), intending to seek external partners for these assets.
Key Financial Metrics
| Metric ($ in thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(19,791) | $(10,008) |
| Operating Expenses | $21,643 | $16,806 |
| Cash and Restricted Cash (Year End) | $2,659 | $3,845 |
| Accumulated Deficit | $(247,252) | $(227,461) |
| Net Cash Used in Operating Activities | $(12,552) | $(16,432) |
| Net Cash Provided by Financing Activities | $10,988 | $7,020 |
Note: The company has no product revenue. Expenses are driven by R&D, G&A, and one-time merger/restructuring costs.
Material Changes vs. Prior Period
- Strategic Pivot: Completed merger with Peak Bio, Inc. in November 2024, acquiring ADC technology and pipeline assets (AKTX-101, PHP-303). Legacy inflammation programs were suspended.
- Operating Loss Increase: Net loss increased 98% to $19.8 million from $10.0 million. This was driven by a 29% increase in operating expenses, primarily due to $3.3 million in merger-related costs and $1.7 million in restructuring costs (reduction-in-force of ~67% of workforce).
- Balance Sheet Impact: Total assets increased significantly to $50.6 million from $4.4 million, largely due to the recognition of $39.2 million in acquired in-process research and development (IPR&D) and $8.4 million in goodwill.
- Debt Assumption: Assumed various notes payable and convertible notes from Peak Bio, totaling approximately $2.2 million in obligations.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern within one year of the report date due to recurring losses and negative cash flows. Additional capital is required to fund operations.
- Liquidity: As of December 31, 2024, cash was $2.6 million. Management expects existing cash plus proceeds from a March 2025 private placement (approx. $6.6 million gross) to fund operations into September 2025.
- Internal Controls: The company identified three material weaknesses in internal control over financial reporting as of December 31, 2024, related to IT general controls, purchase-to-pay processes, and business combination accounting.
- Outlook: Focus is on advancing AKTX-101 to Investigational New Drug (IND) application and initiating first-in-human trials. The company intends to out-license legacy assets to raise capital.
- Risks: High risk of failure in clinical development, inability to secure additional financing, and potential dilution from future equity offerings.
Investor Verification Checklist
- Cash Runway: Verify the closing and net proceeds of the March 2025 private placement to confirm the projected runway into September 2025.
- Merger Integration: Review the status of the Peak Bio integration and the specific timeline for the AKTX-101 IND filing.
- Internal Controls: Monitor progress on remediation of the identified material weaknesses in financial reporting controls.
- Legacy Asset Licensing: Track progress on securing strategic partners for the suspended legacy programs (nomacopan, PHP-303) to generate non-dilutive capital.
- Debt Obligations: Review terms of assumed Peak Bio debt and related party notes to understand immediate repayment requirements.